Inhibition of MHC-I by Brucella abortus is an early event during infection and involves EGFR pathway.
Brucella abortus is able to persist inside the host despite the development of potent CD8+T-cell responses. We have recently reported the ability of B. abortus to inhibit the interferon-γ-induced major histocompatibility complex (MHC)-I cell surface expression on human monocytes. This phenomenon was due to the B. abortus-mediated retention of MHC-I molecules within the Golgi apparatus and was dependent on bacterial viability. However, the implications of bacterial virulence or replicative capacity and the signaling pathways remained unknown. Here we demonstrated that the B. abortus mutant strains RB51 and virB10-are able to inhibit MHC-I expression in the same manner as wild-type B. abortus, even though they are unable to persist inside human monocytes for a long period of time. Consistent with this, the phenomenon was triggered early in time and could be observed at 8 h postinfection. At 24 and 48 h, it was even stronger. Regarding the signaling pathway, targeting epidermal growth factor (EGF) receptor (EGFR), ErbB2 (HER2) or inhibition of tumor necrosis factor-α-converting enzyme, one of the enzymes which generates soluble EGF-like ligands, resulted in partial recovery of MHC-I surface expression. Moreover, recombinant EGF and transforming growth factor-α as well as the combination of both were also able to reproduce the B. abortus-induced MHC-I downmodulation. Finally, when infection was performed in the presence of an extracellular signal-regulated kinase 1/2 (Erk1/2) inhibitor, MHC-I surface expression was significantly recovered. Overall, these results describe how B. abortus evades CD8+T-cell responses early during infection and exploits the EGFR-ERK signaling pathway to escape from the immune system and favor chronicity.
Instituto de Medicina Experimental (CONICET-Academia Nacional de Medicina), Buenos Aires, Argentina.
Lis N
LN
Velásquez
Instituto de Medicina Experimental (CONICET-Academia Nacional de Medicina), Buenos Aires, Argentina.
M Ayelén
MA
Milillo
Instituto de Inmunología, Genética y Metabolismo, Hospital de Clínicas 'José de San Martín', (CONICET/UBA), Buenos Aires, Argentina.
M Victoria
MV
Delpino
Instituto de Medicina Experimental (CONICET-Academia Nacional de Medicina), Buenos Aires, Argentina.
Aldana
A
Trotta
Instituto de Biología y Medicina Experimental (IByME), CONICET, Buenos Aires, Argentina.
M Florencia
MF
Mercogliano
Instituto de Medicina Experimental (CONICET-Academia Nacional de Medicina), Buenos Aires, Argentina.
Roberto G
RG
Pozner
Instituto de Biología y Medicina Experimental (IByME), CONICET, Buenos Aires, Argentina.
Roxana
R
Schillaci
Instituto de Biología y Medicina Experimental (IByME), CONICET, Buenos Aires, Argentina.
Patricia V
PV
Elizalde
Instituto de Inmunología, Genética y Metabolismo, Hospital de Clínicas 'José de San Martín', (CONICET/UBA), Buenos Aires, Argentina.
Guillermo H
GH
Giambartolomei
Instituto de Medicina Experimental (CONICET-Academia Nacional de Medicina), Buenos Aires, Argentina.
Paula
P
Barrionuevo
D000818:Animals; D002003:Brucella abortus / Q000276:immunology* / Q000472:pathogenicity; D002006:Brucellosis / Q000276:immunology* / Q000382:microbiology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000382:microbiology; D066246:ErbB Receptors / Q000378:metabolism*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D005260:Female; D015395:Histocompatibility Antigens Class I / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D057131:Immune Evasion; D051379:Mice; D008810:Mice, Inbred C57BL; D008829:Microbiology; D009000:Monocytes / Q000276:immunology*; D015398:Signal Transduction; D000074084:THP-1 Cells; D015854:Up-Regulation
D015395:Histocompatibility Antigens Class I; C541485:EGFR protein, mouse; D066246:ErbB Receptors; D048049:Extracellular Signal-Regulated MAP Kinases